In fact, sPD-L1 seems to reduce IFN-γ secretion by T cells and it can participate in systemic anti-tumor immune regulation by targeting T lymphocytes in secondary lymphoid organs [11,35,36]. Here, SPDL1 is linked to neoplasm.